Investigation the Inhibitory Effects of Kaempferol on Rat Renalmesangial Cells Proliferation under High Glucose Condition
Abstract
To investigate the protective effects of kaempferol on rat renal mesangial cells under high glucose condition and explore its mechanism. Methods The HBZY-1 cells were divided into normal glucose group (5.5 mmol/L), high glucose group (25 mmol/L), 10 μmol/L kaempferol+high glucose group, and 30 μmol/L kaempferol+high glucose group. Cell proliferative ability was measured by MTT; cell cycle was analyzed by flow cytometry; mRNA and protein levels were determined by Real-time PCR and Western blot, respectively. Results Kaempferol had no effect on the proliferative ability of rat renal mesangial cells under normal glucose (5.5 mmol/L) condition. High glucose (25 mmol/L) enhanced the cell proliferative ability, and this effect was antagonized by kaempferol (10-30 μmol/L) treatment. High glucose reduced the cell population at G0 /G1 2/M phase; and kaempferol treatment restored high glucose-induced changes in cell cycle. Kaempferol also prevented high glucose-induced increase in fibronectin and connective tissue growth factor mRNA and protein expression levels. Kaempferol also prevented high glucose-induced increase in fibronectin and connective tissue growth factor mRNA and protein expression levels. Further, high glucose caused an increase in protein level of phosphorylated p38 mitogen-activated protein kinases (p38 MAPK), which was antagonized by kaempferol treatment. Conclusion Our results suggest that kaempferol exerts its protective effect on rat renal mesangial cells under high glucose condition via p38 MAPK signaling pathway.
Keywords: Kaempferol High glucose, Rat renal mesangial cell p38, MAPK signaling pathway
Full Text:
PDFReferences
YANG W, LU J, WENG J, et at. Prevalence of diabetes among men and women in China. N Engl J Med. 2010, 362 (12);1090-1101.
GNUDI L. Angiopoietins and diabetic nephropathy. Diabetologia,2016,59(8):1616-1620.
COVE-SMITH A, HENDRY BM. The regulation of mesangial cell proliferation. Nephron Exp Nephrol,2008,108 (4):e74-e79.
KAWANAMID, МАТОВА К. UTSUNOMIYA К. Signaling pathways in diabetic nephropathy. Histol Histopathol,2016,31 (10): 1059-1067.
JANG YS, WANG Z, LEE JM, et al. Screening of korean natural products for anti-adipogenesis properties and isolation of kaempferol-3-o-rutinoside as a potent anti-adipogenetic compound from solidago virgaurea. Molecules, 2016,21 (2): pii: E226 [2016-10-11 ]. http://www. mdpi. com/1420-3049/ 21/2/226. doi; 10. 3390/molecules21020226.
KIMSH. CHOI КС. Anti-cancer effect and underlying mechanism ( s) of kaempferol. a phytoestrogen, on the regulation of apoptosis in diverse cancer cell models. Toxicol Res,2013,29(4):229-234.
GUO K. LU J. HUANG Y. et al. Protective role of PGC- 1 alpha in diabetic nephropathy is associated with the inhibition of ROS through mitochondrial dynamic remodeling. PLoS One,2015,10(4): e0125176[2016-10-ll], http://dx. doi. org/10. 1371/journal, pone. 0125176.
WANG J. FANG F. HUANG Z, et al. Kaempferol is an estrogen-related receptor alpha and gamma inverse agonist. FEBS Lett,2009,583(4);643-647. 548 M )
LI XQ. TIAN W, LIU XX, elal. Corosolic acid inhibits the proliferation of glomerular mesangial cells and protects against diabetic renal damage. Sci Rep. 2016,6: 26854 _2016- 10-11]. http://www. nature. com/articles/srep26854. doi; 10. 1038/srep26854.
JIANG XY, LU DB, JIANG YZ, et al. PGC-lalpha prevents apoptosis in adipose-derived stem cells by reducing reactive oxygen species production in a diabetic microenvironment. Diabetes Res Clin Pract, 2013, 100 ( 3): 368-375.
LABAER J, GARRETT MD, STEVENSON LF, et al. New functional activities for the p21 family of CDK inhibitors. Genes Dev, 1997,11(7) ;847-862.
LIU CM, QI XL. YANG YF, et al. Betulinic acid inhibits cell proliferation and fibronectin accumulation in rat glomerular mesangial cells cultured under high glucose condition. Biomed Pharmacother, 2016 ,80; 338-342[2016-10- 11J . http://dx. doi. org,/10. 1016/j. biopha. 2016. 02. 040. ZHU L, ZHAO S, LIU S, et al. PTEN regulates renal extracellular matrix deposit via increased CTGF in diabetes mellitus. J Cell Biochem,2016,117(5): 1187-1198.
KLAASSEN L VAN GEEST RJ, KUIPER EJ, et al. The role of CTGF in diabetic retinopathy. Exp Eye Res, 2015, 133: 37-48 [2016-10-11] . http://dx. org/10. 1016/j. exer. 2014. 10.016.
BAI X» HOU X. TIAN J, et al. CDK5 promotes renal tubulointerstitial fibrosis in diabetic nephropathy via erkl/2/ ppargamma pathway. ()ncotarget,2016,7(24);36510-36528.
WANG X, SHI L, HAN Z, et al. Follistatin-like 3 suppresses cell proliferation and fibronectin expression via p38MAPK pathway in rat mesangial cells cultured under high glucose. Int J Clin Exp Med,2015,8(9); 15214-15221.
WANG Y, WANG Y, LUO M, et al. Novel curcumin analog C66 prevents diabetic nephropathy via JNK pathway with the involvement of p300/CBP-mediated histone acetylation. Biochim Biophys Acta,2015,1852 (1):34-16.
TULI R, TULI S, NANDI S, et al. Transforming growth factor-beta-mediated chondrogenesis of human mesenchymal progenitor cells involves N-cadherin and mitogen-activated protein kinase and Wnt signaling cross-talk. J Biol Chem, 2003.278(42);i1227-41236.
LIU W, LAN T, XIE X, et al. S1P2 receptor mediates sphingosine-l-phosphate-induced fibronectin expression via МАРК signaling pathway in mesangial cells under high glucose condition. Exp Cell Res,2012,318(8) ;936-943.
LI X, LIU W, WANG Q, et al. Emodin suppresses cell proliferation and fibronectin expression via p38MAPK pathway in rat mesangial cells cultured under high glucose. Mol Cell Endocrinol,2009,307( 1/2); 157-162.
JIANG YG, LUO Y, HE DL, et al. Role of Wnt/p-catenin signaling pathway in epithelial-mesenchymal transition of human prostate cancer induced by hypoxia-inducible factor¬ies Int J Urol,2007,14(11); 1034-1039.
DWYER RM, KHAN S. BARRY FP, et al. Advances in mesenchymal stem cell-mediated gene therapy for cancer. Stem Cell Res Ther.2010,1(3) :25.
GLENNIE S, SOEIRO I, DYSON PJ. et al. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood,2005,105(7) ;2821-2827.
AGGARWAL S, PITTENGER MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005,105(4):1815-1822.
CORCIONE A, BENVENUTO F. FERRETTI E. et al. Human mesenchymal stem cells modulate В-cell functions. Blood,2006,107(1);367-372.
SOTIROPOULOU PA, PEREZ SA, GRITZAPIS AD, et al. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells,2006, 24( 1) :74-85.
MOSES MA, WIEDERSCHAIN D. LOUGH LIN KR, et al. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res, 1998,58(7); 1395-1399.
GOHJI K. FUJIMOTO N, HARA I, et al. Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension. Int J Cancer. 1998,79(1);96-101.
STEARNS ME. RHIM J, WANG M. Interleukin 10 (IL- 10) inhibition of primary human prostate cancer-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMD-2/MMP-9 secretion. Clin Cancer Res, 1999, 5 ( 1 ); 189-196.
ZHANG L, SHI J, FENG J. et al. Type IV collagenase ( matrix metalloproteinase-2 and -9 ) in prostate cancer. Prostate Cancer Prostatic Dis,2004 ,7(4); 327-332.
Refbacks
- There are currently no refbacks.
